Results 141 to 150 of about 49,496 (199)
New L‐Dopa Codrugs as Potential Antiparkinson Agents
Archiv der Pharmazie, 2008 AbstractThis paper reports the synthesis and preliminary evaluation of newL‐dopa (LD) conjugates (1and2) obtained by joining LD with two different natural antioxidants, caffeic acid and carnosine, respectively. The antioxidant efficacy of compounds1and2was assessed by evaluating plasmatic activities of superoxide dismutase (SOD) and glutathione ...
SOZIO, Piera +9 more
openaire +6 more sources
REVERSAL OF SOME THERAPEUTIC EFFECTS OF AN ANTIPSYCHOTIC AGENT BY AN ANTIPARKINSONISM DRUG
The Journal of Nervous and Mental Disease, 1973 Data are presented from a multidimensional, longitudinal study in 10 acute schizophrenics which indicate that the addition of benztropine to haloperidol reversed the course of some of the therapeutic changes. The nontherapeutic interaction was selective involving what may be called social avoidance behavior but not the cognitive integrative ...
Man Mohan Singh, James M. Smith
openaire +4 more sources
Quantitative Determination of Some Synthetic Antiparkinsonism Agents
Journal of Pharmaceutical Sciences, 1968 Nonaqueous titrimetry was employed to estimate quantitatively some of the compounds which are useful in treating Parkinsonism. The method was applied to both the crystalline material and their dosage forms. This technique was found to yield results which agreed well with those obtained by either the official procedures or by methods submitted by the ...
W.J. Racz, L.G. Chatten
openaire +4 more sources
Efficacy of antiparkinson agents in preventing antipsychotic-induced extrapyramidal symptoms
American Journal of Health-System Pharmacy, 1979 The types of extrapyramidal syndrome (EPS) reactions produced by antipsychotic agents and the prophylactic use of antiparkinson agents in preventing EPS are reviewed. EPS are classified as akathisias, dystonias, parkinson-like symptoms and tardive dyskinesia, and have a varied incidence reported to range from 10.6 to 100%.
Ronald B. Stewart, John E. Murphy
openaire +4 more sources
Potential antiparkinsonism agents. Quinuclidinyl benzhydryl ethers
Journal of Medicinal Chemistry, 1969 Nilsson Jl, Wågermark J, Dahlbom R
openaire +4 more sources
[Immunotropic activity of a potential antiparkinson agent himantane].
Eksperimental'naia i klinicheskaia farmakologiia, 2001 N-(Adamant-2-yl) hexamethyleneimine hydrochloride (A-7, himantane), a new potential antiparkinsonian drug belonging to the class of aminoadamantyl derivatives, exhibits pronounced immunomodulant activity in a therapeutic dose of 10 mg/kg. A single intraperitoneal injection of himantane stimulated a high B-lymphocyte activity in mice over a period of 21
G I, Nezhinskaia +3 more
openaire +2 more sources
ANTIPARKINSON DRUGS AS CAUSAL AGENTS IN TARDIVE DYSKINESIA
Medical Journal of Australia, 1973 Kiloh Lg, Williams Se, Smith Js
openaire +4 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Carotenoids as Antiparkinson Agents
2021Parkinson’s disease (PD) is a neurodegenerative disease associated with the loss of dopaminergic neurons in the portions of the brain via multiple pathological mechanisms. Despite the fact that enormous progress occurred in the cure of Parkinson’s disorder, but the incidence and risk of this disease is increasing alarmingly over the past few decades ...
Pratik Chakraborty +5 more
openaire +2 more sources
POTENTIAL FOR ABUSE OF ANTIPARKINSON AGENTS
Psychiatric Services, 1982Hospital &‘ Community Psychiatrj is expanding its roster of peer reviewers for manuscripts submitted for publication. Professionals in the mental health disciplines who are qualified to serve as peer reviewers are invited to contact the editor. Reviewers must have significant publications in their specialty area, be abreast of the liteEature in that ...
Winston W. Shen, James Smith
openaire +3 more sources